Patents Assigned to Boehringer Ingelheim International GmbH
  • Patent number: 10435670
    Abstract: Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: October 8, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jonathan Coffman, Jeff Goby, Scott Godfrey, Raquel Orozco, Jens Holger Vogel
  • Patent number: 10413536
    Abstract: 6-Alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Ulrich Reiser
  • Patent number: 10414769
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups A, R and q are defined in claim 1, their use as inhibitors of IGF-1R, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Treu, Stephan Karl Zahn
  • Patent number: 10414828
    Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 17, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
  • Patent number: 10406172
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: September 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Broedl, Rolf Grempler
  • Patent number: 10398654
    Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Masanori Ito, Kenji Egusa, Roman Messerschmid, Peter Schneider
  • Patent number: 10399961
    Abstract: The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: September 3, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Remko Bakker, Riccardo Giovannini, Dieter Hamprecht, Iain Lingard, Alexander Pautsch, Bernd Wellenzohn
  • Patent number: 10391270
    Abstract: A method, an electronic device, a system and an information storage medium for practicing and/or controlling an inhalation process of a patient. The method involves quantifying an airflow in a mouthpiece of an inhaler during an inhalation process of the patient using an inhalation training device, evaluating an airflow signal received from the inhalation training device via an electronic device and providing visual feedback to the patient with the electronic device, the visual feedback varying with one or more time-variant characteristics of the evaluated airflow signal. The electronic device is configured for evaluation of an airflow signal received from an inhalation training device and for provision of visual feedback to the patient, the visual feedback varying with one or more time-variant characteristics of the evaluated signal. The inhalation training system comprises an inhalation training device, an inhaler and the electronic device.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: August 27, 2019
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patricia Adams, Marion Frank, Herbert Wachtel
  • Patent number: 10392419
    Abstract: Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 27, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Martin Fleck, Christian Andreas Kuttruff, Sebastian Carotta
  • Patent number: 10392369
    Abstract: This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: August 27, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec
  • Patent number: 10385134
    Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 20, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
  • Patent number: 10377828
    Abstract: The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Katrin Friedbichler
  • Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Publication number: 20190231766
    Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ulrich BRAUNS, Norbert HAUEL, Peter SIEGER
  • Patent number: 10363559
    Abstract: The invention relates to an apparatus for separating blood and at the same time an apparatus (1) for absorbing blood (19) and separating components such as blood plasma, as a sample liquid (2), having a feed device (13) for receiving the blood (2), a separating device (15) for separating blood components as the sample liquid (2), a channel (3) which takes up the sample liquid (2) preferably exclusively by capillary forces and a fill device for filling the channel (3) with sample liquid (2) in an inlet or feed region (18) of the channel (3), wherein the separating device (15), particularly a membrane, is domed, more particularly convexly shaped and projects with the apex of the convex shape into the filling device in the direction of filling.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 30, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gert Blankenstein, Holger Bartos, Ralf-Peter Peters, Christian Schoen
  • Patent number: 10336729
    Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Andreas Blum, Stefan Peters
  • Patent number: 10328074
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
  • Patent number: RE47493
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: July 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Klaus Rudolf
  • Patent number: RE47636
    Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 8, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch